ENOV Enovis CORP
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1420800 · Fiscal year ends 12/31
Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.3%
TTM net income YoY61.4%
TTM EPS YoY62.1%
Revenue 3-yr CAGR11.6%
Net income 3-yr CAGR—
Margins
Gross margin61.3%
Operating margin-20.6%
Net margin-22.9%
FCF margin3.0%
EBITDA margin37.7%
Returns
ROE-30.0%
ROA-12.9%
ROIC (approx.)-12.3%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets60.0%
Debt / equity0.84x
Current ratio2.15x
Interest coverage-14.69x
Cash quality & payout
Operating cash flow / net income-0.49x
Accruals ratio-19.3%
Payout ratio—
Capex / revenue8.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.25B | $2.11B |
| Cost of revenue | $902.79M | $926.87M |
| Gross profit | $1.35B | $1.18B |
| R&D expense | $120.33M | $91.30M |
| SG&A expense | $1.07B | $1.03B |
| Operating income | -$1.12B | -$775.72M |
| Interest expense | $34.82M | $57.10M |
| Pretax income | -$1.16B | -$822.92M |
| Income tax | $22.29M | $4.49M |
| Net income | -$1.18B | -$825.49M |
| EBITDA | $219.89M | $152.11M |
| EPS (basic) | -20.75 | -14.93 |
| EPS (diluted) | -20.75 | -14.93 |
| Weighted avg. shares (diluted) | 57.07M | 55.28M |
| Balance sheet | ||
| Cash & equivalents | $36.39M | $48.17M |
| Receivables | $442.79M | $407.03M |
| Inventory | $584.38M | $547.12M |
| Current assets | $1.21B | $1.15B |
| PP&E, net | $507.06M | $404.50M |
| Goodwill | $718.30M | $1.69B |
| Intangibles | $1.24B | $1.32B |
| Total assets | $3.83B | $4.72B |
| Current liabilities | $598.47M | $529.00M |
| Short-term debt | $35.00M | $20.03M |
| Long-term debt | $1.26B | $1.31B |
| Total debt | $1.30B | $1.33B |
| Total liabilities | $2.34B | $2.15B |
| Shareholders' equity | $1.49B | $2.56B |
| Net debt | $1.26B | $1.28B |
| Shares outstanding | 57.19M | 55.88M |
| Cash flow statement | ||
| Operating cash flow | $217.29M | $113.50M |
| Capital expenditure | $197.38M | $180.71M |
| Free cash flow | $19.92M | -$67.21M |
| Investing cash flow | -$179.37M | -$955.47M |
| Financing cash flow | -$52.40M | $846.82M |
| Depreciation & amortization | $1.34B | $927.83M |
| Stock-based compensation | $32.92M | $29.66M |
| Share buybacks | $3.50M | $4.77M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.